Sign up to receive GE SmartMail.

DaTscan for Your Patients About DaTscan

Educational Video Series for DaTscan

Watch these informative videos to learn more about
single-photon emission computed tomography (SPECT)
imaging with DaTscan.


How dopamine transporter visualization can assist in diagnosis
Dr. Russell illustrates the value of visualizing dopamine transporter density to help differentiate between parkinsonian syndromes and nonparkinsonian disorders such as essential tremor. He then guides us through visualization of dopamine terminals using brain SPECT imaging with DaTscan and discusses his views on medication trials in the
diagnostic workup.


Misdiagnosis happens more than
we realize

Dr. Russell explains how common it can be for members of the medical community to provide an incorrect diagnosis of a parkinsonian syndrome when a range of other neurological conditions is encountered. After reviewing a challenging case from his own practice, he explains how brain SPECT imaging with DaTscan has helped improve his ability to
assess patients.


When “watch and wait” is not a
good strategy

Dr. Russell discusses the drawbacks of always taking a “watch and wait” approach to diagnosing patients who may have a parkinsonian syndrome. He then explains how using brain SPECT imaging with DaTscan at the beginning of patient evaluations has helped him decide if a parkinsonian syndrome is not present and gain clearer
diagnostic perspective.


Challenges that lead to misdiagnosis
Dr. Henchcliffe outlines four patient types whose symptoms can lead
to an inconclusive diagnosis or a misdiagnosis of a parkinsonian syndrome or essential tremor. She
also explains how brain SPECT imaging with DaTscan has helped her evaluate those challenging patient types and reach a differential diagnosis.


Seeing the difference starts with
the radiologist

Dr. Kuo provides an overview of his best practices that help him ensure the accuracy of brain SPECT imaging with DaTscan. Additionally, he discusses interpreting DaTscan images and how to best convey scan results to neurologists to help them reach a differential diagnosis.


Introduction to DaTscan
Learn how DaTscan may be used
as an adjunct to other diagnostic
evaluations to help differentiate
essential tremor from tremor due
to parkinsonian syndromes.


Mechanism of Action
This video provides a visual animation of the mechanism of action for DaTscan. It demonstrates how DaTscan works and how it can help in the evaluation process.


Imaging Atlas for DaTscan
Dr. John Seibyl, of the Institute for Neurodegenerative Disorders in New Haven, Connecticut, provides an overview of imaging guidelines and case studies of imaging tests
using DaTscan.

PRODUCT INDICATIONS AND USE: DaTscan (Ioflupane I 123 Injection) is a radiopharmaceutical indicated for striatal dopamine transporter visualization using single-photon emission computed tomography (SPECT) brain imaging to assist in the evaluation of adult patients with suspected parkinsonian syndromes (PSs). DaTscan may be used to help differentiate essential tremor from tremor due to PS (idiopathic Parkinson’s disease [PD], multiple system atrophy [MSA], and progressive supranuclear palsy [PSP]). DaTscan is an adjunct to other diagnostic evaluations. DaTscan was not designed to distinguish among PD, MSA, and PSP. The effectiveness of DaTscan as a screening or confirmatory test and for monitoring disease progression or response to therapy has not been established.

Important Risk and Safety Information About DaTscan

CONTRAINDICATIONS: DaTscan is contraindicated in patients with known hypersensitivity to the active substance, any of the excipients, or iodine. WARNINGS AND PRECAUTIONS — Hypersensitivity Reactions: Hypersensitivity reactions, generally consisting of skin erythema and pruritus, have been reported following DaTscan administration. Thyroid Accumulation: The DaTscan injection may contain up to 6% of free iodide (iodine 123 or I-123). To decrease thyroid accumulation of I-123, block the thyroid gland at least one hour before administration of DaTscan; failure to do so may increase the long-term risk for thyroid neoplasia. ADVERSE REACTIONS: In clinical trials, headache, nausea, vertigo, dry mouth, or dizziness of mild to moderate severity were reported. In postmarketing experience, hypersensitivity reactions and injection-site pain have been reported. DRUG INTERACTIONS: Drugs that bind to the dopamine transporter with high affinity may interfere with the DaTscan image. The impact of dopamine agonists and antagonists on DaTscan imaging results has not been established. SPECIFIC POPULATIONS — Pregnancy: It is unknown whether DaTscan can cause fetal harm or increase the risk of pregnancy loss in pregnant women. DaTscan should be given to pregnant women only if clearly needed. Like all radiopharmaceuticals, DaTscan may cause fetal harm, depending on the stage of fetal development and the magnitude of the radionuclide dose. Radioactive iodine products cross the placenta and can permanently impair fetal thyroid function. Nursing Mothers: It is not known whether DaTscan is excreted into human milk; however, I-123 is excreted into human milk. Because many drugs are excreted into human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to interrupt nursing after administration of DaTscan or not to administer DaTscan at all. Nursing women may consider interrupting nursing and pumping and discarding breast milk for six days after DaTscan administration to minimize risks to a nursing infant. Pediatric Use: The safety and efficacy of DaTscan have not been established in pediatric patients. Geriatric Use: There were no differences in responses between the elderly and younger patients that would require a dose adjustment. Renal and Hepatic Impairment: The effect of renal or hepatic impairment on DaTscan imaging has not been established. The kidney excretes DaTscan; patients with severe renal impairment may have increased radiation exposure and altered DaTscan images. OVERDOSAGE: It is unknown whether or not ioflupane is dialyzable. The major risks of overdose relate to increased radiation exposure and long-term risk for neoplasia. In case of radioactivity overdosage, frequent urination and defecation should be encouraged to minimize radiation exposure to the patient. PROCEDURE — Radiation Safety: DaTscan emits radiation and must be handled with safety measures to minimize radiation exposure to clinical personnel and patients.

Prior to DaTscan administration, please read the Full Prescribing Information.